Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
5.14
+0.03 (0.59%)
At close: Jul 21, 2025, 4:00 PM
5.09
-0.05 (-0.97%)
After-hours: Jul 21, 2025, 7:51 PM EDT

Xeris Biopharma Holdings Stock Forecast

Stock Price Forecast

The 6 analysts that cover Xeris Biopharma Holdings stock have a consensus rating of "Strong Buy" and an average price target of $6.25, which forecasts a 21.6% increase in the stock price over the next year. The lowest target is $4 and the highest is $8.

Price Target: $6.25 (+21.6%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$4.00$6.25$6.50$8.00
Change-22.18%+21.60%+26.46%+55.64%
* Price targets were last updated on May 9, 2025.

Analyst Ratings

The average analyst rating for Xeris Biopharma Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy233333
Buy122222
Hold111111
Sell000000
Strong Sell000000
Total466666

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Oppenheimer
Oppenheimer
Buy
Maintains
$6$7
BuyMaintains$6$7+36.19%May 9, 2025
Leerink Partners
Leerink Partners
Buy
Maintains
$5$6
BuyMaintains$5$6+16.73%Mar 7, 2025
Craig-Hallum
Craig-Hallum
Strong Buy
Maintains
$5$6.5
Strong BuyMaintains$5$6.5+26.46%Mar 7, 2025
Piper Sandler
Piper Sandler
Hold
Reiterates
$3$4
HoldReiterates$3$4-22.18%Mar 7, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$6.6$8
Strong BuyReiterates$6.6$8+55.64%Mar 7, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
274.77M
from 203.07M
Increased by 35.31%
Revenue Next Year
328.77M
from 274.77M
Increased by 19.65%
EPS This Year
-0.09
from -0.37
EPS Next Year
0.11
from -0.09
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
20.44M49.59M110.25M163.91M203.07M274.77M328.77M384.87M
Revenue Growth
650.74%142.67%122.32%48.68%23.89%35.31%19.65%17.06%
EPS
-2.14-1.55-0.70-0.45-0.37-0.090.110.36
EPS Growth
-------220.45%
Forward PE
------45.8114.30
No. Analysts
-----887
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High285.3M357.6M434.6M
Avg274.8M328.8M384.9M
Low259.9M294.5M342.5M

Revenue Growth

Revenue Growth20252026202720282029
High
40.5%
30.2%
32.2%
Avg
35.3%
19.7%
17.1%
Low
28.0%
7.2%
4.2%

EPS Forecast

EPS202520262027
High-0.040.220.46
Avg-0.090.110.36
Low-0.16-0.150.23

EPS Growth

EPS Growth202520262027
High--
311.8%
Avg--
220.5%
Low--
100.9%
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.